KinDex was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease. KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction. TAS2Rs are found in multiple tissue types and regulate hormones that play a key role in chronic disease such as Polycystic Ovary Syndrome (PCOS), obesity, NASH and diabetes. Our lead candidate, KDT501, is an orally dosed, small molecule modulator of TAS2Rs that has been demonstrated safe and effective in Phase 1 and 2 clinical trials. Our next goal is to study the effects of KDT501 in patients with PCOS. PCOS is a common endocrine disorder affecting between 5 and 10 % of women of reproductive age1. Many PCOS patients have a family history of diabetes or insulin resistance or a close relative who is similarly affected by androgen excess. Irregular ovulation in combination with excess androgens, excess hair growth (hirsutism), acne and obesity can all occur in women with PCOS. Women with PCOS are at greater risk for type 2 diabetes and cardiovascular disease and possibly hypertension and abnormal lipid levels.
Show more
Type
Private
HQ
Seattle, US
Founded
2009
Size (employees)
2 (est)
KinDex Pharmaceuticals was founded in 2009 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at KinDex Pharmaceuticals

Jeffrey Bland

Jeffrey Bland

President and CEO
Lincoln Bouillon

Lincoln Bouillon

Chief Financial Officer
Neile Grayson

Neile Grayson

Vice President, Drug Development

KinDex Pharmaceuticals Office Locations

KinDex Pharmaceuticals has an office in Seattle
Seattle, US (HQ)
4100 Bank of America Fifth Avenue Plaza 800 5th Ave
Show all (1)
Report incorrect company information

KinDex Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$5.8 m

Latest funding size

$327.27 k

Time since last funding

2 years ago
KinDex Pharmaceuticals's latest funding round in August 2016 was reported to be $327.3 k. In total, KinDex Pharmaceuticals has raised $5.8 m
Show all financial metrics
Report incorrect company information